Copaxone was approved as an NDA through 505(b) that is why the FDA accepted Sandoz’s ANDA for review. However, given its complexities, I don't believe the FDA will treat this other than a biologic drug - meaning full clinical trials to demonstrate safety and efficacy will be required. We need not further debate on that, just wait for the anticipated FoB legislation to pass.
Market Data 
Markets 
AI
